Acute pulmonary embolism is rare during childhood and adolescence. The high pulmonary embolism-related fatality among ...

Akura Medical, Inc., a privately held portfolio company of Shifamed LLC that is developing treatments for venous thromboembolis ...

Outpatient management of patients with cancer-associated pulmonary embolism (PE) may be a feasible, safe approach with low short-term rates of recurrent venous thromboembolism (VTE), major bleeding, ...

Learn more about whether Inari Medical, Inc. or DENTSPLY SIRONA Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Bausch + Lomb Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Drug Delivery From ATK to BTK: What Is on the Horizon? With moderator Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed(ClinEpi), and panelists Marianne Brodmann, MD; Osamu ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Inari Medical Inc., one of Orange County’s fastest-growing medical device makers, is being acquired for $4.9 billion by global medical technology company Stryker Corp. Stryker on Jan. 6 announced an ...

In this article, we are going to take a look at where Inari Medical Inc. (NASDAQ:NARI) stands against the other stocks. Ten companies finished stronger this week, outpacing the broader market ...

Acquisition expected to strengthen Stryker’s neurovascular business with Inari VTE product portfolio including mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein ...